Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Oncofertility
  • Reduced price
Complete Accounts of Integrated Drug Discovery and Development

Complete Accounts of Integrated Drug Discovery and Development

Recent Examples from the Pharmaceutical Industry, Volume 3

9780841298644
897.00 zł
807.30 zł Save 89.70 zł Tax included
Lowest price within 30 days before promotion: 807.30 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
Case studies from the pharmaceutical industryThis book describes the continuum from discovery to development. Readers will learn how recent drugs, including grazoprevir, melflufen, relebactam, and tesirine, were developed. The book highlights emerging concepts, new developments, and challenges during the discovery process. Well-known authors from the pharmaceutical industry provide an inside look to traditionally closed-door procedures. Profssional chemists and students alike will find these accounts extremely valuable.
Product Details
OUP USA
92120
9780841298644
9780841298644

Data sheet

Publication date
2022
Issue number
1
Cover
hard cover
Pages count
400
Dimensions (mm)
178 x 254
Weight (g)
1082
  • Preface ; Chapter 1: Discovery and Chemical Development of the Use-Dependent Sodium Channel Blocker Vixotrigine for the Treatment of Pain, David R. Witty, David T. MacPherson, Gerard M. P. Giblin, Michael T. Williams, Robbie Chen, Vinny Couming, John Guzowski, Erwin Irdam, William F. Kiesman, Daw-Iong Albert Kwok, Wenli Liang, Tamera L. Mack, Erin M. OBrien, Suzanne M. Opalka, Daniel Patience, Stefan Sahli, Donald G. Walker, and FrederickOsei-Yeboah; Chapter 2: The Discovery and Chemical Development of BMS-919373: A Selective IKur Inhibitor for the Potential Treatment of Atrial Fibrillation, Heather J. Finlay, Scott A. Savage, Jason M. Stevens, Steven R. Wisniewski, and Miao Yu; Chapter 3: Discovery and Development of Omecamtiv Mecarbil: A Novel Cardiac Myosin Activator for the Potential Treatment of Systolic Heart Failure, Bradley P. Morgan, Seb Caille, and Shawn D. Walker; Chapter 4: Identification and Development of AMG 986: A Potent and Efficacious APJ Agonist for the Treatment of Heart Failure, Matthew R. Kaller, Paul Dransfield, Robert P. Farrell, and Ted C. Judd; Chapter 5: Melflufen: A Journey from Discovery to Multi-Kilogram Production, Fredrik Lehmann and Johan Wennerberg; Chapter 6: Discovery and Chemical Development of S 44563, a Dual Bcl-2/Bcl-xL Inhibitor, Christophe Hardouin and Jerome-Benoit Starck; Chapter 7: Discovery and Chemical Development of Tesirine: An Antitumor Pyrrolobenzodiazepine Antibody-Drug Conjugate Drug-Linker, Arnaud C. Tiberghien and Jeremy S. Parker; Chapter 8: Discovery and Chemical Development of Relebactam: A Potent Beta-Lactamase Inhibitor in Combination with PrimaxinR for the Treatment of Serious and Antibiotic-Resistant Bacterial Infections, Feng Xu, Benjamin D. Sherry, and Timothy A. Blizzard; Chapter 9: Discovery and Chemical Development of Grazoprevir: An HCV NS3/4a Protease Inhibitor for the Treatment of the Hepatitis C Virus Infection, Feng Xu and John A. McCauley; Chapter 10: Discovery and Process Development of BIIB068: A Reversible Brutons Tyrosine Kinase (BTK) Inhibitor for the Treatment of Autoimmune Diseases, Bin Ma, Chaomin Li, Brian T. Hopkins, Lloyd Franklin, Robbie Chen, Tamera Mack, Daniel Patience, William F. Kiesman, and Erin M. OBrien; Chapter 11: Discovery and Commercial Development of Cholesteryl Transfer Protein Inhibitor Evacetrapib, Nathan B. Mantlo and Scott A. Frank; Editors Biographies; Author Index; Subject Index ;
Comments (0)

  • Frequently purchased together

    No products available